CRSP (CRISPR Therapeutics AG) Cyclically Adjusted PS Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CRSP CRISPR Therapeutics AG CRSP
31 GF Score
Price $58.33
! 2 Warning Signs
View Full Analysis

What is CRISPR Therapeutics AG Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


CRISPR Therapeutics AG  (NAS:CRSP) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


CRISPR Therapeutics AG Cyclically Adjusted PS Ratio Related Terms


CRISPR Therapeutics AG Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for CRISPR Therapeutics AG's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CRISPR Therapeutics AG Cyclically Adjusted PS Ratio Chart

CRISPR Therapeutics AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 23.88 16.28 21.64

CRISPR Therapeutics AG Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.94 26.66 20.74 18.67 21.23

CRSP vs LGND, DFTX, XENE: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, CRISPR Therapeutics AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CRISPR Therapeutics AG Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where CRISPR Therapeutics AG's Cyclically Adjusted PS Ratio falls into.


CRSP
31GF Score
CRISPR Therapeutics AG CRSP
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CRISPR Therapeutics AG Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

CRISPR Therapeutics AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, CRISPR Therapeutics AG's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.105/108.5600*108.5600
=0.105

Current CPI (Jun. 2026) = 108.5600.

CRISPR Therapeutics AG Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.293 99.604 0.319
201612 0.059 99.380 0.064
201703 0.068 100.040 0.074
201706 0.090 100.285 0.097
201709 0.060 100.254 0.065
201712 0.776 100.213 0.841
201803 0.030 100.836 0.032
201806 0.023 101.435 0.025
201809 0.012 101.246 0.013
201812 0.002 100.906 0.002
201903 0.006 101.571 0.006
201906 0.006 102.044 0.006
201909 3.679 101.396 3.939
201912 1.279 101.063 1.374
202003 0.003 101.048 0.003
202006 0.001 100.743 0.001
202009 0.002 100.585 0.002
202012 0.005 100.241 0.005
202103 0.007 100.800 0.008
202106 11.196 101.352 11.992
202109 0.011 101.533 0.012
202112 0.168 101.776 0.179
202203 0.012 103.205 0.013
202206 0.002 104.783 0.002
202209 0.001 104.835 0.001
202212 0.000 104.666 0.000
202303 1.271 106.245 1.299
202306 0.885 106.576 0.901
202309 0.000 106.570 0.000
202312 2.474 106.461 2.523
202403 0.006 107.355 0.006
202406 0.006 107.991 0.006
202409 0.007 107.468 0.007
202412 0.418 107.128 0.424
202503 0.010 107.722 0.010
202506 0.010 108.075 0.010
202509 0.010 107.710 0.010
202512 0.009 107.200 0.009
202603 0.015 108.060 0.015
202606 0.105 108.560 0.105

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CRISPR Therapeutics AG Business Description

Address Baarerstrasse 14, Zug, CHE, 6300
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
31GF Score

Get the complete analysis for CRSP

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$58.33
Price